GoodRx Holdings, Inc. (NASDAQ:GDRX) Holdings Decreased by American Century Companies Inc.

American Century Companies Inc. trimmed its holdings in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) by 52.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,038,610 shares of the company's stock after selling 2,247,295 shares during the period. American Century Companies Inc. owned approximately 0.53% of GoodRx worth $9,480,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Charles Schwab Investment Management Inc. increased its stake in GoodRx by 5.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 480,123 shares of the company's stock valued at $3,332,000 after buying an additional 26,262 shares during the period. Centiva Capital LP increased its stake in shares of GoodRx by 27.5% during the third quarter. Centiva Capital LP now owns 66,233 shares of the company's stock valued at $460,000 after acquiring an additional 14,287 shares during the period. Point72 Asset Management L.P. acquired a new position in shares of GoodRx during the third quarter valued at approximately $11,295,000. EP Wealth Advisors LLC bought a new stake in GoodRx during the third quarter worth approximately $73,000. Finally, Pier Capital LLC acquired a new stake in GoodRx in the third quarter worth approximately $3,259,000. 63.77% of the stock is currently owned by institutional investors.

GoodRx Trading Down 2.7 %

GDRX stock traded down $0.11 during mid-day trading on Monday, reaching $4.01. 1,615,029 shares of the stock traded hands, compared to its average volume of 1,373,234. GoodRx Holdings, Inc. has a 52-week low of $3.82 and a 52-week high of $9.26. The stock's fifty day moving average is $4.71 and its 200-day moving average is $5.14. The company has a market cap of $1.54 billion, a P/E ratio of -133.67, a P/E/G ratio of 2.46 and a beta of 1.25. The company has a current ratio of 5.48, a quick ratio of 5.48 and a debt-to-equity ratio of 0.70.

Remove Ads

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Wells Fargo & Company lowered their price target on GoodRx from $9.00 to $8.00 and set an "overweight" rating on the stock in a research report on Friday, February 28th. Morgan Stanley lowered their target price on GoodRx from $7.00 to $6.00 and set an "equal weight" rating on the stock in a report on Tuesday, December 17th. Citigroup cut their price target on shares of GoodRx from $7.00 to $6.25 and set a "buy" rating for the company in a report on Friday, January 10th. Finally, KeyCorp lowered their price objective on shares of GoodRx from $7.00 to $6.00 and set an "overweight" rating on the stock in a research note on Wednesday, January 8th. Three investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $8.18.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.